Company Information

  

Address: 99 HAYDEN AVENUE, SUITE 230  
City: LEXINGTON 
State: MA 
Zip Code: 02421 
Telephone: 781-778-7720 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. Our lead investigational product candidate is oncology therapeutic XBIO-101 (`sodium cridanimod') for the treatment of progestin - resistant endometrial cancer. We have exclusive rights to develop and commercialize XBIO-101 worldwide, except for specified countries in the Commonwealth of Independent States ("CIS"), including Russia. XBIO-101 has been granted orphan drug designation by the U.S. Food and Drug Administration ("FDA") for the potential treatment of progesterone receptor negative ("PrR-") endometrial cancer in conjunction with progesterone therapy. We are currently conducting a Phase 2 trial for XBIO-101, with the first patient dosed in October 2017, and expect to generate preliminary data from this trial before the end of 2018.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2018-0.18NAN/E
03/2018-0.28NAN/E
12/2017-0.41NAN/E
09/2017-1.23NAN/E
06/2017-0.23NAN/E
03/2017-7.40NAN/E
12/2016-7.84NAN/E
09/2016-8.41NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.02Total Liab/Total Assets0.25
Net Inc/Total Assets-0.19Total Liab/Inv Cap0.28
Net Inc/Inv Cap-0.21Total Liab/Comm Equity0.03
Pretax Inc/Net Sales-0.47Interest Coverage Ratio-1976.52
Net Inc/Net Sales-0.47Curr Debt/EquityNA
Cash Flow/Net Sales0.20LTD/EquityNA
SG&A/NetSales0.91Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover5.06Quick Ratio3.03
Inventory TurnoverNACurrent Ratio3.03
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap1.92Inv/Curr AssetsNA
Net Sales/PP&E272.39  

Income Statement (Millions)

  6/30/2018 3/31/2018 12/31/2017 9/30/2017
Total Revenues(Net Sales) NA NA 7.50 0.09
Cost of Goods Sold 0.00 NA 0.00 0.10
Selling & Admin Exps 1.07 1.12 1.99 1.34
Operating Income -1.99 -1.83 4.43 -2.24
Interest Exp NA NA 0.00 0.00
Pretax Income -2.03 -1.82 4.45 -2.26
Other Income -0.03 0.01 0.01 -0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -2.03 -1.82 4.45 -2.26

Balance Sheet (Millions)

Assets 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Cash & Short Term Investments 3.32 3.93 5.60 0.76
Receivables - Total NA NA 0.00 0.04
Inventories - Total NA NA NA NA
Total Current Assets 4.00 4.28 5.88 2.05
Net Property, Plant & Equipment 0.02 0.02 0.03 0.03
Total Assets 17.26 17.54 19.16 14.64
Liabilities        
Accounts Payable 1.54 1.72 1.92 2.14
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 1.55 1.74 1.94 2.16
Long-Term Debt NA NA NA NA
Total Liabilities 4.47 4.66 4.86 5.08
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -149.78 -147.76 -145.93 -150.38
Treasury Stock -5.28 -5.28 -5.28 -5.28
Total Stockholders' Equity 12.78 12.89 14.30 9.55
Total Liabilities and Stockholders' Equity 17.26 17.54 19.16 14.64

Cash Flow Summary (Millions)

Categories 6/30/2018 3/31/2018 12/31/2017 9/30/2017
Net Cash Provided by Operating Activities -2.09 -1.67 4.84 -1.64
Net Cash Provided by Investing Activities 0.00 0.00 0.00 0.00
Net Cash Provided by Financing Activities 1.48 0.00 0.00 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20131.00-8.58--
12/20140.00-14.31--
12/20150.00-12.51--
12/20163.00-54.21-7.84
12/20177.58-3.60-0.41
Growth Rates65.95----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1893433.66




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.